Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Iovance Biotherapeutics (IOVA) over the last 3 years, with Q3 2025 value amounting to $6.8 million.

  • Iovance Biotherapeutics' Change in Receivables fell 7176.38% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year decrease of 8028.73%. This contributed to the annual value of $69.2 million for FY2024, which is 4633557.05% up from last year.
  • Per Iovance Biotherapeutics' latest filing, its Change in Receivables stood at $6.8 million for Q3 2025, which was down 7176.38% from -$11.0 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Change in Receivables registered a high of $31.4 million during Q2 2024, and its lowest value of -$11.0 million during Q2 2025.
  • Moreover, its 3-year median value for Change in Receivables was $873500.0 (2023), whereas its average is $6.7 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 9496060.61% in 2024, then tumbled by 13506.53% in 2025.
  • Iovance Biotherapeutics' Change in Receivables (Quarter) stood at $149000.0 in 2023, then skyrocketed by 9008.72% to $13.6 million in 2024, then tumbled by 49.73% to $6.8 million in 2025.
  • Its Change in Receivables was $6.8 million in Q3 2025, compared to -$11.0 million in Q2 2025 and $1.6 million in Q1 2025.